FIELD: biotechnology; chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a method of producing an antibody or an antigen-binding fragment thereof, which binds to CLDN6. Also disclosed is a recombinant nucleic acid encoding the produced antibody; vector containing said nucleic acid; recombinant cell containing said nucleic acid; polypeptide encoded by said nucleic acid. Disclosed is a method of producing said recombinant eukaryotic host cell.
EFFECT: invention enables to efficiently obtain an antibody or its antigen-binding fragment, which binds to CLDN6.
32 cl, 10 ex, 1 tbl, 37 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
